Abstract
New Orleans, La. From Obatala Sciences, Inc. Received for publication July 6, 2021; accepted September 30, 2021. Disclosure:The author is a co-founder, co-owner, and chief scientific officer of Obatala Sciences, Inc., and LaCell, LLC, for-profit biotechnology companies focusing on the clinical translation of adipose-derived cells and extracellular matrix products for regenerative medicine. He is also a co-owner and co-founder of Talaria Antibodies, Inc., and the inventor on patents related to adipose and stromal/stem cell research applications. Jeffrey M. Gimble, M.D., Ph.D., Obatala Sciences, Inc., 2000 Lakeshore Drive, Suite 4020, New Orleans, La. 70122 [email protected]
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
